Page 9 - Lifes Work News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Take to prevent serious illness. the one from pfizer that was approved yesterday appears to be more effective and appears to have potentially fewer side effects and safety concerns than the one that was approved from work today. the pfizer one appears to be the preferable option from merck. both in terms of effectiveness and complications. but the one from pfizer, the better one, isn't really, really limited supply and will be for a long while yet. no one, the one that is not as good or as useful for a lot of people, there is more supply of that one. but again, it's not as effective and it has...

Are both done for the year wrapping up their business last week and high tailed it home for the holidays. the house will be back january 10 but the senate is coming back a week earlier than that which is notable for other reasons meaning they will be back in session january 6, and that is a controversial thing in terms of elected officials and say, capitol police officers want to be at work and at the capitol on january 6 given what happened on that date one year ago. that said, there is also a real urgency to get right to work at the start of the year given the list of things they are hoping ...

Boosted, you can get a breakthrough case but for people who get infected who are at high risk of getting seriously ill and trying to stay out of the hospital, our country have had pretty good success with the monoclonal antibody treatments as a series of injections. but the bad news about monoclonal antibody treatments that saved so people and helped so many people over the recent months, the bad news is that the two most commonly used ones, they don't work against the omicron variant. that said, there is a third monoclonal antibody, and that is less available and harder to get and is in very ...

Washington d.c. has a relatively small population, and when big things happen to small populations, things can look warped when you look at the chart, and honestly, look at the chart and washington d.c. and the new covid cases. this is the washington d.c. chart of new covid cases reported overtime. look at the right side of that graph. it looks like a glitch. it looks like somebody dropped it. right? but that is not a typo. that is real and if you want a slice of life in washington in terms of people who live and work in washington d.c. who you heard of a lot of high-profile cases, senator cor...

That have done so well for so many people over all these recent months, the bad news about them right now is that the two most commonly used ones, the one from lily and the one from regeneron, they don't work against the omicron variant. that said there is a third monoclonal anti bodies, that when made by glaxosmithkline, that one is harder to get. but that one does work against omicron. and there is a very interesting story about the administration realizing that early on, as soon as omicron reared its head. the on the initiation has been trying hard to marshal its resources of that one monoc...